VALBIOTIS SA (ALVAL.PA) Stock Price & Overview
EPA:ALVAL • FR0013254851
Current stock price
The current stock price of ALVAL.PA is 1.01 EUR. Today ALVAL.PA is down by -0.2%. In the past month the price decreased by -5.78%. In the past year, price decreased by -0.59%.
ALVAL.PA Key Statistics
- Market Cap
- 23.937M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.53
- Dividend Yield
- N/A
ALVAL.PA Stock Performance
ALVAL.PA Stock Chart
ALVAL.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ALVAL.PA. When comparing the yearly performance of all stocks, ALVAL.PA is one of the better performing stocks in the market, outperforming 79.46% of all stocks.
ALVAL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALVAL.PA. Both the profitability and financial health of ALVAL.PA have multiple concerns.
ALVAL.PA Earnings
ALVAL.PA Forecast & Estimates
11 analysts have analysed ALVAL.PA and the average price target is 2.24 EUR. This implies a price increase of 122.18% is expected in the next year compared to the current price of 1.01.
For the next year, analysts expect an EPS growth of 25.36% and a revenue growth 400% for ALVAL.PA
ALVAL.PA Groups
Sector & Classification
ALVAL.PA Financial Highlights
Over the last trailing twelve months ALVAL.PA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS increased by 15.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.45% | ||
| ROE | -135.28% | ||
| Debt/Equity | 0.45 |
ALVAL.PA Ownership
ALVAL.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 29.8 | 42.737B | ||
| ARGX | ARGENX SE | 29.63 | 42.687B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.644B | ||
| ABVX | ABIVAX SA | N/A | 7.77B | ||
| 2X1 | ABIVAX SA | N/A | 7.751B | ||
| GXE | GALAPAGOS NV | N/A | 1.641B | ||
| GLPG | GALAPAGOS NV | N/A | 1.626B | ||
| NANO | NANOBIOTIX | N/A | 1.275B | ||
| PHARM | PHARMING GROUP NV | 48.19 | 1.029B | ||
| PHGN | PHARMING GROUP NV | 48.32 | 1.028B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 997.606M | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALVAL.PA
Company Profile
Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine and currently employs 50 full-time employees. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Company Info
IPO: 2017-06-07
VALBIOTIS SA
12F rue Paul Vatine
Perigny NOUVELLE-AQUITAINE FR
Employees: 50
VALBIOTIS SA / ALVAL.PA FAQ
What does ALVAL do?
Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine and currently employs 50 full-time employees. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
What is the stock price of VALBIOTIS SA today?
The current stock price of ALVAL.PA is 1.01 EUR. The price decreased by -0.2% in the last trading session.
Does VALBIOTIS SA pay dividends?
ALVAL.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALVAL stock?
ALVAL.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting ALVAL stock to perform?
11 analysts have analysed ALVAL.PA and the average price target is 2.24 EUR. This implies a price increase of 122.18% is expected in the next year compared to the current price of 1.01.
Can you provide the sector and industry classification for VALBIOTIS SA?
VALBIOTIS SA (ALVAL.PA) operates in the Health Care sector and the Biotechnology industry.